

[Notes to editors]

1. Product Details

1) Product Name

Pariet® Tablets 5 mg

2) Generic Name

Rabeprazole sodium

3) Indications

Treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, Zollinger-Ellison syndrome, non-erosive gastroesophageal reflux disease, prevention of recurrent gastric or duodenal ulcers caused by low-dose aspirin therapy

As an adjunct to *H. pylori* eradication in the following diseases:

Gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early-stage gastric cancer, and *H. pylori* gastritis

4) Dosage and Administration (this excerpt is taken only from the section on the prevention of recurrent gastric or duodenal ulcers caused by low-dose aspirin therapy)

For the prevention of recurrent gastric or duodenal ulcers caused by low-dose aspirin therapy

The usual adult dose for oral use is 5 mg of rabeprazole sodium administered once daily. However, the dosage may be increased up to 10 mg orally once daily depending on the severity of symptoms.

5) Listed Price

70.50 yen per tablet

6) Packaging

100 tablets (PTP sheet, bottle), 140 tablets (14 tablet PTP sheet x 10)

[Product Image]

2. About Pariet

Pariet is a proton pump inhibitor (PPI) that was discovered and developed by Eisai. First launched in Japan in 1997, it is approved in more than 100 countries and regions worldwide. In Japan, Pariet is available in 10 mg and 20 mg tablet formulations and is indicated for the treatment of various t

gastric ulcer, duodenal ulcer, reflux esophagitis, non-erosive gastroesophageal reflux disease, and as an adjunctive therapy in *Helicobacter pylori* (*H. pylori*) eradication in patients with gastric ulcer, duodenal ulcer, or *H. pylori* gastritis. Furthermore, in February 2014, the company launched triple formulation combination packs containing Pariet Tablets 10 mg for *H. pylori* eradication, Rabecure Pack (for primary *H. pylori* eradication), and Rabefine Pack (for secondary *H. pylori* eradication).

In December 2014, Pariet was approved for the additional indication of prevention of recurrent gastric or duodenal ulcers caused by low-dose aspirin therapy. In addition, the company is conducting a Phase III study on Pariet in Japan as a maintenance therapy for patients with reflux esophagitis resistant to PPI treatment.